Plain-English translation of NCT05984810 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called SGM-101—a special glowing dye—can help surgeons see pancreatic cancer more clearly during surgery. The dye is injected a few days before your surgery and then glows under special infrared lights that the surgeon uses during the operation. The goal is to help the surgeon know exactly where the cancer is and whether it can be safely removed.
Pancreatic cancer is very difficult to treat and often caught late. Even with surgery and chemotherapy, survival rates remain low. After patients receive chemotherapy or radiation before surgery, it becomes hard for doctors to tell on regular imaging scans where the actual cancer is versus where inflammation and scarring from treatment are. This medication could help surgeons see the real cancer during surgery and make better decisions about what can be safely removed.
You likely qualify if…
You likely don't qualify if…
If you are enrolled, you will receive a single injection of SGM-101 intravenously (into your vein) about 3 to 5 days before your planned pancreatic cancer surgery. During your surgery, the surgeon will use special near-infrared imaging equipment to look for the glowing dye in your tumor. After surgery, tissue samples may also be imaged with this special camera to check for the fluorescent signal. Your participation will be complete after your surgery and these imaging procedures are done.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Netherlands